KDR and neoplasm: Targeted therapies, including vascular endothelial growth factor (VEGF) and its receptor (VEGFR) inhibitors, as well as multi-kinase inhibitors (MKIs), interfere with tumor cell growth, proliferation, metastasis, and survival, providing some survival benefits for HCC patients.